Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression

BMC Pulmonary Medicine

Volumn 10, Issue , 2010, Pages

  Bournazos, Stylianos ^a,b   Grinfeld, Jacob ^a   Alexander, Karen M ^a   Murchison, John T ^c   Wallace, William A ^a,c   McFarlane, Pauline ^c   Hirani, Nikhil ^a,c   Simpson, A John ^a,c   Dransfield, Ian ^a   Hart, Simon P ^d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; FC RECEPTOR IIA; FC RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENE FREQUENCY; GENOTYPE; HOMOZYGOTE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; ALLELE; CASE CONTROL STUDY; CHRONIC DISEASE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; CHRONIC DISEASE; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; RESPIRATORY FUNCTION TESTS;

EID: 77957376786     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-10-51     Document Type: Article

References (49)

1. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001, 164(9):1722-1727.
2. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008, 63(Suppl 5):v1-58.
3. Ward PA. Immune complex injury of the lung. Am J Pathol 1979, 97(1):85-92. 2042385, 158982.
4. Bódi I, Váradi P, Pokorny G, Engelhardt J, Dibó G, Vécsei L, Miko TL. Polyneuropathy with endoneurial immune complex deposition as the first manifestation of systemic lupus erythematosus. Acta Neuropathol 1998, 96(3):297-300. 10.1007/s004010050897, 9754963.
5. Digeon M, Droz D, Noel LH, Riza J, Rieumailhol C, Bach JF, Santoro F, Capron A. The role of circulating immune complexes in the glomerular disease of experimental hepatosplenic schistosomiasis. Clin Exp Immunol 1979, 35(3):329-337. 1537623, 378479.
6. Tarzi RM, Cook HT. Role of Fcγ receptors in glomerulonephritis. Nephron Exp Nephrol 2003, 95(1):e7-12. 10.1159/000073018, 14520009.
7. Bellon B, Bernaudin JF, Mandet C, Chamak B, Kuhn J, Druet P. Immune complex-mediated lung injury produced by horseradish peroxidase (HRP) and anti-HRP antibodies in rats. Am J Pathol 1982, 107(1):16-24. 1915991, 7039334.
8. Dall'Aglio PP, Pesci A, Bertorelli G, Brianti E, Scarpa S. Study of immune complexes in bronchoalveolar lavage fluids. Respiration 1988, 54(Suppl 1):36-41. 10.1159/000195495, 3231904.
9. Dreisin RB, Schwarz MI, Theofilopoulos AN, Stanford RE. Circulating immune complexes in the idiopathic interstitial pneumonias. N Engl J Med 1978, 298(7):353-357. 10.1056/NEJM197802162980701, 146160.
10. Gelb AF, Dreisen RB, Epstein JD, Silverthorne JD, Bickel Y, Fields M, Border WA, Taylor CR. Immune complexes, gallium lung scans, and bronchoalveolar lavage in idiopathic interstitial pneumonitis-fibrosis. Chest 1983, 84(2):148-153. 10.1378/chest.84.2.148, 6872593.
11. Haslam PL, Thompson B, Mohammed I, Townsend PJ, Hodson ME, Holborow EJ, Turner-Warwick M. Circulating immune complexes in patients with cryptogenic fibrosing alveolitis. Clin Exp Immunol 1979, 37(3):381-390. 1537788, 315841.
12. Martinet Y, Haslam PL, Turner-Warwick M. Clinical significance of circulating immune complexes in 'lone' cryptogenic fibrosing alveolitis and those with associated connective tissue disorders. Clin Allergy 1984, 14(5):491-497. 10.1111/j.1365-2222.1984.tb02233.x, 6333299.
13. Gadek J, Hunninghake G, Zimmerman R, Kelman J, Fulmer J, Crystal RG. Pathogenetic studies in idiopathic pulmonary fibrosis. Control of neutrophil migration by immune complexes. Chest 1979, 75(2 Suppl):264-265. 10.1378/chest.75.2_Supplement.264, 155510.
14. Dobashi N, Fujita J, Murota M, Ohtsuki Y, Yamadori I, Yoshinouchi T, Ueda R, Bandoh S, Kamei T, Nishioka M, et al. Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 2000, 178(3):171-179. 10.1007/s004080000020, 10871435.
15. Takahashi T, Wada I, Ohtsuka Y, Munakata M, Homma Y, Kuroki Y. Autoantibody to alanyl-tRNA synthetase in patients with idiopathic pulmonary fibrosis. Respirology 2007, 12(5):642-653. 10.1111/j.1440-1843.2007.01140.x, 17875050.
16. Wallace WA, Roberts SN, Caldwell H, Thornton E, Greening AP, Lamb D, Howie SE. Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis. Thorax 1994, 49(3):218-224. 10.1136/thx.49.3.218, 1021149, 8202877.
17. Bournazos S, Woof JM, Hart SP, Dransfield I. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol 2009, 157(2):244-254. 10.1111/j.1365-2249.2009.03980.x, 2730850, 19604264.
18. Warmerdam PA, van de Winkel JG, Gosselin EJ, Capel PJ. Molecular basis for a polymorphism of human Fc γ receptor II (CD32). J Exp Med 1990, 172(1):19-25. 10.1084/jem.172.1.19, 2188138, 2141627.
19. American Thoracic Society, European Respiratory Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002, 165(2):277-304. American Thoracic Society, European Respiratory Society.
20. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168(5):543-548. 10.1164/rccm.200209-1112OC, 12773329.
21. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168(5):531-537. 10.1164/rccm.200210-1245OC, 12791580.
22. Hanson D, Winterbauer RH, Kirtland SH, Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995, 108(2):305-310. 10.1378/chest.108.2.305, 7634857.
23. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal immunology 2009, 2(2):103-121. 10.1038/mi.2008.85, 2675823, 19129758.
24. Karassa FB, Trikalinos TA, Ioannidis JPA, . Investigators F-SM-A Role of the Fcγ receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 2002, 46(6):1563-1571. 10.1002/art.10306, 12115187, Investigators F-SM-A.
25. Yamamoto K, Kobayashi T, Grossi S, Ho AW, Genco RJ, Yoshie H, De Nardin E. Association of Fcγ receptor IIa genotype with chronic periodontitis in Caucasians. J Periodontol 2004, 75(4):517-522. 10.1902/jop.2004.75.4.517, 15152814.
26. Wolf DL, Neiderud AM, Hinckley K, Dahlén G, van de Winkel JGJ, Papapanou PN. Fcγ receptor polymorphisms and periodontal status: a prospective follow-up study. J Clin Periodontol 2006, 33(10):691-698. 10.1111/j.1600-051X.2006.00973.x, 16889631.
27. van der Pol WL, van den Berg LH, Scheepers RH, van der Bom JG, van Doorn PA, van Koningsveld R, van den Broek MC, Wokke JH, van de Winkel JG. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome. Neurology 2000, 54(8):1661-1665.
28. Daëron M. Fc receptor biology. Annu Rev Immunol 1997, 15:203-234. 10.1146/annurev.immunol.15.1.203, 9143687.
29. Botto M, Theodoridis E, Thompson EM, Beynon HL, Briggs D, Isenberg DA, Walport MJ, Davies KA. FcγRIIa polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clin Exp Immunol 1996, 104(2):264-268. 10.1046/j.1365-2249.1996.33740.x, 2200413, 8625518.
30. Chen J-Y, Wang C-M, Wu J-M, Ho H-H, Luo S-F. Association of rheumatoid factor production with FcγRIIIa polymorphism in Taiwanese rheumatoid arthritis. Clin Exp Immunol 2006, 144(1):10-16. 10.1111/j.1365-2249.2006.03021.x, 1809643, 16542359.
31. Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson MG, Kimberly RP. FcγRIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996, 97(5):1348-1354. 10.1172/JCI118552, 507190, 8636449.
32. Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Tokuda M, Hojo S, Bandou S, Ueda Y, et al. Circulating cytokeratin 8:anti-cytokeratin 8 antibody immune complexes in sera of patients with pulmonary fibrosis. Respiration 2000, 67(4):397-401. 10.1159/000029537, 10940793.
33. Zorzetto M, Ferrarotti I, Trisolini R, Agli LL, Scabini R, Novo M, De Silvestri A, Patelli M, Martinetti M, Cuccia M, et al. Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168(3):330-334. 10.1164/rccm.200302-221OC, 12773320.
34. Kubistova Z, Mrazek F, Lympany PA, Lagan AL, Arakelyan A, Kriegova E, Welsh KI, Kolek V, Zatloukal J, Hutyrova B, et al. The CR1 C5507G polymorphism is not involved in susceptibility to idiopathic pulmonary fibrosis in two European populations. Tissue Antigens 2008, 72(5):483-486. 10.1111/j.1399-0039.2008.01133.x, 18937792.
35. Hodgson U, Tukiainen P, Laitinen T. The polymorphism C5507G of complement receptor 1 does not explain idiopathic pulmonary fibrosis among the Finns. Respir Med 2005, 99(3):265-267. 10.1016/j.rmed.2004.08.003, 15733500.
36. Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006, 3(4):357-363. 10.1513/pats.200601-010TK, 16738201.
37. Antoniou KM, Alexandrakis MG, Sfiridaki K, Tsiligianni I, Perisinakis K, Tzortzaki EG, Siafakas NM, Bouros DE. Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon γ-1b (IFN-γ-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). Sarcoidosis, vasculitis, and diffuse lung diseases 2004, 21(2):105-110.
38. Standiford TJ, Rolfe MR, Kunkel SL, Lynch JP, Becker FS, Orringer MB, Phan S, Strieter RM. Altered production and regulation of monocyte chemoattractant protein-1 from pulmonary fibroblasts isolated from patients with idiopathic pulmonary fibrosis. Chest 1993, 103(2 Suppl):121S. 10.1378/chest.103.2_Supplement.121S, 8428531.
39. Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN. Enhanced IL-1β and tumor necrosis factor-α release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol 1993, 150(9):4188-4196.
40. Checa M, Ruiz V, Montaño M, Velázquez-Cruz R, Selman M, Pardo A. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum Genet 2008, 124(5):465-472. 10.1007/s00439-008-0571-z, 18853190.
41. Molina-Molina M, Xaubet A, Li X, Abdul-Hafez A, Friderici K, Jernigan K, Fu W, Ding Q, Pereda J, Serrano-Mollar A, et al. Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression. Eur Respir J 2008, 32(4):1004-1008. 10.1183/09031936.00015808, 18508830.
42. Mushiroda T, Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, Ogura T, Taniguchi H, Kubo M, Kamatani N, Nakamura Y, et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet 2008, 45(10):654-656. 10.1136/jmg.2008.057356, 18835860.
43. Pantelidis P, Fanning GC, Wells AU, Welsh KI, Du Bois RM. Analysis of tumor necrosis factor-α, lymphotoxin-α, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001, 163(6):1432-1436.
44. Riha RL, Yang IA, Rabnott GC, Tunnicliffe AM, Fong KM, Zimmerman PV. Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. Intern Med J 2004, 34(3):126-129. 10.1111/j.1444-0903.2004.00503.x, 15030461.
45. Selman M, Lin H-M, Montaño M, Jenkins AL, Estrada A, Lin Z, Wang G, DiAngelo SL, Guo X, Umstead TM, et al. Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Genet 2003, 113(6):542-550. 10.1007/s00439-003-1015-4, 13680361.
46. Vasakova M, Striz I, Dutka J, Slavcev A, Jandova S, Kolesar L, Sulc J. Cytokine gene polymorphisms and high-resolution-computed tomography score in idiopathic pulmonary fibrosis. Respir Med 2007, 101(5):944-950. 10.1016/j.rmed.2006.09.013, 17056243.
47. Whittington HA, Freeburn RW, Godinho SIH, Egan J, Haider Y, Millar AB. Analysis of an IL-10 polymorphism in idiopathic pulmonary fibrosis. Genes Immun 2003, 4(4):258-264. 10.1038/sj.gene.6363959, 12761561.
48. Xaubet A, Marin-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, Rodriguez-Becerra E, Rodriguez-Arias JM, Inigo P, Sanz S, et al. Transforming growth factor-β1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168(4):431-435. 10.1164/rccm.200210-1165OC, 12746254.
49. Whyte M, Hubbard R, Meliconi R, Whidborne M, Eaton V, Bingle C, Timms J, Duff G, Facchini A, Pacilli A, et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms. Am J Respir Crit Care Med 2000, 162(2 Pt 1):755-758.